SEC Filing Summary: Manhattan Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 10, 2006, by Manhattan Pharmaceuticals, Inc. (Note: The request metadata lists "TG THERAPEUTICS, INC.", but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.). The report addresses a material error discovered during the financial closing process for the period ended June 30, 2006, affecting the interim financial statements for the quarter ended March 31, 2006.
Key Financial Metrics and Adjustments
The filing details a restatement of the March 31, 2006, Form 10-QSB to correct the classification of a research and development (R&D) expense. The specific adjustments are as follows:
- Prepaid Expenses: Increase of $416,798.
- Research and Development Expenses: Reduction of $416,798.
- Material Commitment Disclosure: Disclosure of a $2,151,840 commitment for a Phase IIa study of Oleoyl-estrone (obesity product candidate).
- Original Invoice Error: An initial invoice of $430,368 was incorrectly recorded entirely as R&D expense. It should have been recorded as $13,570 in R&D expenses and $416,798 in prepaid expenses.
The filing text does not provide clear values for total revenue, net profit, cash flow, margins, or total debt for the period.
Material Changes Versus Prior Period
The primary material change is the reclassification of $416,798 from R&D expenses to prepaid expenses for the quarter ended March 31, 2006. This correction increases reported assets and reduces reported expenses for that specific quarter. The company states that the error was inadvertent and does not believe it will affect reported results for any other past or future periods.
Guidance, Outlook, and Risks
Management Commentary: The Audit Committee concluded that the previously issued interim financial statements should no longer be relied upon. The company intends to amend the Form 10-QSB on or about August 14, 2006. The error was discovered during the June 30, 2006, closing process.
Risks and Contingencies: The filing highlights a material commitment of $2,151,840 for a research and development agreement that was not previously disclosed in the March 31, 2006, report. The Audit Committee has discussed these matters with the independent registered public accounting firm, J.H. Cohn LLP.
Key Facts for Investor Verification
- Verify the amended Form 10-QSB filing expected around August 14, 2006, to confirm the restated financial figures.
- Confirm the status and funding requirements of the $2,151,840 Phase IIa study commitment for Oleoyl-estrone.
- Review the company's internal controls regarding the classification of R&D invoices and prepaid expenses.
- Note the discrepancy between the request metadata (TG THERAPEUTICS, INC.) and the filing registrant (Manhattan Pharmaceuticals, Inc.).